information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Tuesday, 1 July 2014

3°- Is Cystic fibrosis disease a potential target for Biocontrol?

old post:

Tuesday, 20 July 2010



In a patient whit cystic fibrosis disease
the main obstacle, as a consequence of a biocontrol (phage therapy) treatment could be a possible dangerous developping reaction both to local level and/or to general level, caused by a massive release of endotoxin from lysed bacteria.


At moment we do not have data about this possible negative side effect by phage administration but in the Historical document (
AD NUMBER AD837021)* is described a real application which does not provide any information about this question.
*"Aerosol treatment was administered every day. The duration of the individual sessions usually lasted 10-15 minutes. The average number of inhalations administered amounted to 11, the smallest number was 3 (this involved a subchronical tracheobronchitis), and the largest number was 40".

Herxheimer reaction


From:

Bacterial Endotoxin in Human Disease



If we want to avoid this side effect we must study a specific administration cycle for a patient with cystic fibrosis in terms of:

- Phage Dose
- Treatment
Lenght
- Treatment Number
-
Endotoxin Monitoring



My idea is to prepare a specific Phage cocktail and to add to this cocktail a proporzionate quantity of Polymyxin B* ( in this case the evaluations regarding the potential damages for toxicity by use of Polymyxin B must be made before all ).

 



Main Drug= Phages
LPS neutralizing= Polymyxin B





Polymyxin B is present for neutralizing the LPS that is released from phage- lysed bacteria.

Finally, after test, to use this synergetic composition by:
-aerosol therapy (Phages and Polymyxin B together or alternatively to use two close and separeted aerosol administrations, Phages before and Polymyxin B after )
 or 
-Phages by aereosol and Polymyxin B by hemoperfusion .